In this scenario, the receptor tyrosine kinase RET (REarranged during Transfection) has emerged as a new player in ER+ cancer development as well as a potential target to enhance sensitivity of BC to tamoxifen therapy and to avoid tamoxifen resistance [16]. Here, ESR1 is linked to breast cancer.